Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Landec Corp (LNDC) Stock Forecast & Price Prediction United States | NASDAQ | |
$4.86
+0.25 (5.42%)Did LNDC Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Landec is one of their latest high-conviction picks.
LNDC has shown a year-to-date change of -40.6% and a 1-year change of -36.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for LNDC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for LNDC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 7, 2022 | Barrington Research | Michael Petusky | Outperform | Maintains | $12.00 |
| Aug 11, 2022 | Barrington Research | Michael Petusky | Outperform | Upgrade | $14.00 |
| Jul 20, 2022 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Apr 6, 2022 | Barrington Research | Market Perform | Downgrade | $N/A | |
| Oct 4, 2021 | Roth Capital | Gerry Sweeney | Buy | Maintains | $14.00 |
| Jul 30, 2021 | Roth Capital | Buy | Maintains | $15.00 | |
| Jun 2, 2021 | Barrington Research | Outperform | Upgrade | $N/A | |
| Apr 9, 2021 | Roth Capital | Buy | Maintains | $12.00 | |
| Jan 6, 2020 | Barrington Research | Market Perform | Downgrade | $N/A | |
| Sep 3, 2019 | Barrington Research | Outperform | Initiates | $N/A | |
| Aug 23, 2019 | DA Davidson | Buy | Initiates | $N/A | |
| Apr 8, 2019 | Roth Capital | Neutral | Downgrade | $N/A | |
| Jul 8, 2016 | Wedbush | Neutral | Initiates | $N/A | |
| Jun 7, 2016 | Maxim Group | Buy | Initiates | $N/A | |
| Apr 2, 2015 | Imperial Capital | Outperform | Maintains | $18.00 | |
| Oct 9, 2014 | Feltl & Co. | Downgrade | $10.00 | ||
| Apr 14, 2014 | Northland Securities | Outperform | Maintains | $N/A | |
| Apr 14, 2014 | Northland Capital Markets | Outperform | Maintains | $14.00 | |
| Apr 1, 2014 | Imperial Capital | Outperform | Initiates | $N/A | |
| Mar 10, 2014 | Lake Street | Buy | Initiates | $N/A |
The following stocks are similar to Landec based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Landec Corp has a market capitalization of $143.83M with a P/E ratio of -1.5x. The company generates $185.79M in trailing twelve-month revenue with a 27.1% profit margin.
Revenue growth is -9.0% quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +164.0%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
N/A
N/A
N/A
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical (NASDAQ: LFCR) shareholders over allegations of misleading business information. Affected investors may seek compensation with no upfront costs.
Allegations of misleading information from Lifecore Biomedical could lead to legal actions and potential compensation for shareholders, impacting stock value and investor sentiment.
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical (NASDAQ: LFCR) shareholders due to allegations of misleading business information. Affected investors may seek compensation with no upfront costs.
Allegations of misleading information by Lifecore Biomedical could lead to legal claims, impacting stock value and shareholder compensation potential, influencing investor sentiment.
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical Inc. (NASDAQ: LFCR), due to allegations of misleading business information. Affected shareholders may seek compensation.
Allegations of misleading information could lead to legal actions against Lifecore Biomedical, potentially impacting its stock price and shareholder value.
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical Inc. shareholders due to allegations of misleading business information. Investors may seek compensation without upfront costs.
Allegations of misleading information from Lifecore Biomedical could lead to legal claims, impacting stock value and investor sentiment. Potential compensation may arise for affected shareholders.
Rosen Law Firm is investigating potential securities claims for Lifecore Biomedical Inc. shareholders over allegations of misleading business information. Affected investors may seek compensation without upfront costs.
Allegations of misleading information from Lifecore Biomedical could lead to legal claims, impacting investor confidence and stock value, potentially resulting in financial compensation for affected shareholders.
Landec Corporation (Nasdaq: LNDC) will have CEO Jim Hall and CFO John Morberg speak at the Stephens Annual Investment Conference in Nashville, TN.
CEO and CFO presentations signal potential insights into Landec's strategy and performance, influencing investor sentiment and stock valuation.
Analyst forecasts for Landec Corp (LNDC) are not currently available. The stock is trading at $4.86.
According to current analyst ratings, LNDC has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.86. Always conduct your own research and consider your investment goals before making investment decisions.
Price predictions from Wall Street analysts for LNDC are not currently available. The stock is trading at $4.86.
N/A
Price targets from Wall Street analysts for LNDC are not currently available. The stock is trading at $4.86.
Price targets from Wall Street analysts for LNDC are not currently available. The stock is trading at $4.86.
The overall analyst consensus for LNDC is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
Stock price projections, including those for Landec Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.